Marco Marzioni
Overview
Explore the profile of Marco Marzioni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
6074
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvaruso V, Celsa C, Cristoferi L, Scaravaglio M, Smith R, Kaur S, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39674236
Background & Aims: Noninvasive tests (NITs) for ruling-out clinical significant portal hypertension (CSPH) and high-risk varices (HRVs) in patients with primary biliary cholangitis (PBC) and compensated advanced chronic liver disease...
2.
Marzioni M, Crino S, Lisotti A, Fuccio L, Vanella G, Amato A, et al.
Surg Endosc
. 2024 Sep;
38(11):6207-6226.
PMID: 39317905
Background: Malignant Distal Biliary Obstruction (MBDO) is a common event occurring along the natural history of both pancreatic cancer and cholangiocarcinoma. Epidemiological and biological features make MBDO one of the...
3.
van Keulen A, Buettner S, Olthof P, Klumpen H, Erdmann J, Izquierdo-Sanchez L, et al.
Ann Surg Oncol
. 2024 Jun;
31(10):6495-6503.
PMID: 38896226
Background: Resection of perihilar cholangiocarcinoma (pCCA) is a complex procedure with a high risk of postoperative mortality and early disease recurrence. The objective of this study was to compare patient...
4.
Manieri V, Offidani M, Capelli D, Marzioni M, Maroni L, Filosa A, et al.
Ann Hematol
. 2024 Jun;
103(9):3783-3786.
PMID: 38871930
Amyloid Light Chain (AL) Amyloidosis is a rare disorder of protein misfolding and metabolism characterized by insoluble fibrils deposition in various tissues and organs, which could quickly progress and become...
5.
De Vincentis A, Ampuero J, Terracciani F, DAmato D, Gerussi A, Cristoferi L, et al.
Clin Gastroenterol Hepatol
. 2024 May;
22(10):2062-2074.e11.
PMID: 38782175
Background & Aims: Obeticholic acid (OCA) is the only licensed second-line therapy for primary biliary cholangitis (PBC). With novel therapeutics in advanced development, clinical tools are needed to tailor the...
6.
Balducci D, Montori M, Martini F, Valvano M, De Blasio F, Argenziano M, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611050
Endoluminal biliary radiofrequency ablation (RFA) has been proposed as a palliative treatment for patients with malignant biliary obstruction (MBO) in order to improve stent patency and survival. However, the existing...
7.
Nayagam J, Weismuller T, Milkiewicz P, Wronka K, Bik E, Schramm C, et al.
JHEP Rep
. 2023 Dec;
6(1):100951.
PMID: 38089547
Background & Aims: Although worsening liver-related symptoms during pregnancy can occur in primary sclerosing cholangitis (PSC), there are insufficient data to effectively counsel patients on their pre-conception risk and no...
8.
Martini F, Balducci D, Mancinelli M, Buzzanca V, Fracchia E, Tarantino G, et al.
J Clin Med
. 2023 Sep;
12(17).
PMID: 37685780
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease with a heterogeneous presentation, symptomatology, disease progression, and response to therapy. The current risk stratification assessment, aimed at identifying patients...
9.
Montori M, Scorzoni C, Argenziano M, Balducci D, De Blasio F, Martini F, et al.
J Clin Med
. 2022 Nov;
11(21).
PMID: 36362726
Cholangiocarcinoma (CCA) is an aggressive neoplasia with an increasing incidence and mortality. It is characterized by a strong desmoplastic stroma surrounding cancer cells. Cancer-associated fibroblasts (CAFs) are the main cell...
10.
Balducci D, Quatraccioni C, Benedetti A, Marzioni M, Maroni L
Explor Target Antitumor Ther
. 2022 Sep;
2(2):174-186.
PMID: 36046145
Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer...